{"pmid":32501455,"pmcid":"PMC7252041","title":"Down Syndrome and COVID-19: A Perfect Storm?","text":["Down Syndrome and COVID-19: A Perfect Storm?","People with Down syndrome show signs of chronic immune dysregulation, including a higher prevalence of autoimmune disorders, increased rates of hospitalization during respiratory viral infections, and higher mortality rates from pneumonia and sepsis. At the molecular and cellular levels, they show markers of chronic autoinflammation, including interferon hyperactivity, elevated levels of many inflammatory cytokines and chemokines, and changes in diverse immune cell types reminiscent of inflammatory conditions observed in the general population. However, the impact of this immune dysregulation in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and CoV disease of 2019 (COVID-19) remains unknown. This Perspective outlines why individuals with Down syndrome should be considered an at-risk population for severe COVID-19. Specifically, the immune dysregulation caused by trisomy 21 may result in an exacerbated cytokine release syndrome relative to that observed in the euploid population, thus justifying additional monitoring and specialized care for this vulnerable population.","Cell Rep Med","Espinosa, Joaquin M","32501455"],"abstract":["People with Down syndrome show signs of chronic immune dysregulation, including a higher prevalence of autoimmune disorders, increased rates of hospitalization during respiratory viral infections, and higher mortality rates from pneumonia and sepsis. At the molecular and cellular levels, they show markers of chronic autoinflammation, including interferon hyperactivity, elevated levels of many inflammatory cytokines and chemokines, and changes in diverse immune cell types reminiscent of inflammatory conditions observed in the general population. However, the impact of this immune dysregulation in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and CoV disease of 2019 (COVID-19) remains unknown. This Perspective outlines why individuals with Down syndrome should be considered an at-risk population for severe COVID-19. Specifically, the immune dysregulation caused by trisomy 21 may result in an exacerbated cytokine release syndrome relative to that observed in the euploid population, thus justifying additional monitoring and specialized care for this vulnerable population."],"journal":"Cell Rep Med","authors":["Espinosa, Joaquin M"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501455","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.xcrm.2020.100019","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668804508702998528,"score":9.490897,"similar":[{"pmid":32467561,"pmcid":"PMC7255975","title":"Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.","text":["Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.","To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments. Therefore, based on the fast and global spread of the virus, urgent investigations are warranted in order to develop preventive and therapeutic drugs. In this regard, treatments addressing the immunopathology of SARS-CoV-2 infection have become a major focus. Notably, while a rapid and well-coordinated immune response represents the first line of defense against viral infection, excessive inflammatory innate response and impaired adaptive host immune defense may lead to tissue damage both at the site of virus entry and at systemic level. Several studies highlight relevant changes occurring both in innate and adaptive immune system in COVID-19 patients. In particular, the massive cytokine and chemokine release, the so-called \"cytokine storm\", clearly reflects a widespread uncontrolled dysregulation of the host immune defense. Although the prospective of counteracting cytokine storm is compelling, a major limitation relies on the limited understanding of the immune signaling pathways triggered by SARS-CoV-2 infection. The identification of signaling pathways altered during viral infections may help to unravel the most relevant molecular cascades implicated in biological processes mediating viral infections and to unveil key molecular players that may be targeted. Thus, given the key role of the immune system in COVID-19, a deeper understanding of the mechanism behind the immune dysregulation might give us clues for the clinical management of the severe cases and for preventing the transition from mild to severe stages.","Signal Transduct Target Ther","Catanzaro, Michele","Fagiani, Francesca","Racchi, Marco","Corsini, Emanuela","Govoni, Stefano","Lanni, Cristina","32467561"],"abstract":["To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments. Therefore, based on the fast and global spread of the virus, urgent investigations are warranted in order to develop preventive and therapeutic drugs. In this regard, treatments addressing the immunopathology of SARS-CoV-2 infection have become a major focus. Notably, while a rapid and well-coordinated immune response represents the first line of defense against viral infection, excessive inflammatory innate response and impaired adaptive host immune defense may lead to tissue damage both at the site of virus entry and at systemic level. Several studies highlight relevant changes occurring both in innate and adaptive immune system in COVID-19 patients. In particular, the massive cytokine and chemokine release, the so-called \"cytokine storm\", clearly reflects a widespread uncontrolled dysregulation of the host immune defense. Although the prospective of counteracting cytokine storm is compelling, a major limitation relies on the limited understanding of the immune signaling pathways triggered by SARS-CoV-2 infection. The identification of signaling pathways altered during viral infections may help to unravel the most relevant molecular cascades implicated in biological processes mediating viral infections and to unveil key molecular players that may be targeted. Thus, given the key role of the immune system in COVID-19, a deeper understanding of the mechanism behind the immune dysregulation might give us clues for the clinical management of the severe cases and for preventing the transition from mild to severe stages."],"journal":"Signal Transduct Target Ther","authors":["Catanzaro, Michele","Fagiani, Francesca","Racchi, Marco","Corsini, Emanuela","Govoni, Stefano","Lanni, Cristina"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32467561","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1038/s41392-020-0191-1","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887132504065,"score":205.65878},{"pmid":32480422,"title":"Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.","text":["Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia.","In December 2019, a novel coronavirus pneumonia, coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China. A hyperinflammatory immune response, or cytokine release syndrome (CRS) is observed in critically unwell patients with SARS-CoV-2 globally. Severe lymphopenia, hyperactivated pro-inflammatory T cells(1) and decreased regulatory T cells(2) are seen in these critically ill patients, suggesting dysregulated immune responses.","Br J Haematol","Ranger, Amita","Haji, Ruby","Kaczmarski, Richard","Danga, Akila","32480422"],"abstract":["In December 2019, a novel coronavirus pneumonia, coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China. A hyperinflammatory immune response, or cytokine release syndrome (CRS) is observed in critically unwell patients with SARS-CoV-2 globally. Severe lymphopenia, hyperactivated pro-inflammatory T cells(1) and decreased regulatory T cells(2) are seen in these critically ill patients, suggesting dysregulated immune responses."],"journal":"Br J Haematol","authors":["Ranger, Amita","Haji, Ruby","Kaczmarski, Richard","Danga, Akila"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32480422","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/bjh.16901","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Case Report"],"weight":1,"_version_":1668532089511739393,"score":204.64261},{"pmid":32460144,"title":"Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions.","text":["Altered cytokine levels and immune responses in patients with SARS-CoV-2 infection and related conditions.","The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic in early 2020. The infection has been associated with a wide range of clinical symptoms. In the severely affected patients, it has caused dysregulation of immune responses including over-secretion of inflammatory cytokines and imbalances in the proportion of naive helper T cells, memory helper T cells and regulatory T cells. Identification of the underlying mechanism of such aberrant function of immune system would help in the prediction of disease course and selection of susceptible patients for more intensive cares. In the current review, we summarize the results of studies which reported alterations in cytokine levels and immune cell functions in patients affected with SARS-CoV-2 and related viruses.","Cytokine","Noroozi, Rezvan","Branicki, Wojciech","Pyrc, Krzysztof","Labaj, Pawel P","Pospiech, Ewelina","Taheri, Mohammad","Ghafouri-Fard, Soudeh","32460144"],"abstract":["The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic in early 2020. The infection has been associated with a wide range of clinical symptoms. In the severely affected patients, it has caused dysregulation of immune responses including over-secretion of inflammatory cytokines and imbalances in the proportion of naive helper T cells, memory helper T cells and regulatory T cells. Identification of the underlying mechanism of such aberrant function of immune system would help in the prediction of disease course and selection of susceptible patients for more intensive cares. In the current review, we summarize the results of studies which reported alterations in cytokine levels and immune cell functions in patients affected with SARS-CoV-2 and related viruses."],"journal":"Cytokine","authors":["Noroozi, Rezvan","Branicki, Wojciech","Pyrc, Krzysztof","Labaj, Pawel P","Pospiech, Ewelina","Taheri, Mohammad","Ghafouri-Fard, Soudeh"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32460144","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.cyto.2020.155143","keywords":["cytokine","immune cells","sars-cov"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967698944917505,"score":197.48541},{"pmid":32237901,"pmcid":"PMC7157951","title":"Immune-epidemiological parameters of the novel coronavirus - a perspective.","text":["Immune-epidemiological parameters of the novel coronavirus - a perspective.","Introduction: At the end of 2019, Wuhan, a city in China with a population of about 11 million, witnessed the outbreak of unusual pneumonia. As of 29 March 2020, the disease has spread to more 199 countries and territories worldwide. The 2019 novel coronavirus, 2019-nCoV, is known as the probable causative agent of the illness.Areas covered: Here, the epidemiological dynamics of the coronavirus disease 2019 (COVID-19) that stand in close relation to distinct immunogenetic characters of the pathogen are discussed, to understand the ability and inability of the immune system in combatting COVID-19.Expert opinion: The elderly population is at increased risk of developing and dying from COVID-19. Comorbidity is present in more than 30% of cases with COVID-19. Except for less than 1% of the total, a chronic condition has been found in all cases that died from COVID-19. Men are more than 1.5 times more likely to die from COVID-19. Evidence links aging to cytokine dysregulation and T-cell repertoire reduction, male population to relatively reduced anti-viral immunity, and COVID-19-related comorbidities to hyper inflammation. The transmission of COVID-19 is influenced by the host-related factors that are known to be associated with immune dysregulation.","Expert Rev Clin Immunol","Saghazadeh, Amene","Rezaei, Nima","32237901"],"abstract":["Introduction: At the end of 2019, Wuhan, a city in China with a population of about 11 million, witnessed the outbreak of unusual pneumonia. As of 29 March 2020, the disease has spread to more 199 countries and territories worldwide. The 2019 novel coronavirus, 2019-nCoV, is known as the probable causative agent of the illness.Areas covered: Here, the epidemiological dynamics of the coronavirus disease 2019 (COVID-19) that stand in close relation to distinct immunogenetic characters of the pathogen are discussed, to understand the ability and inability of the immune system in combatting COVID-19.Expert opinion: The elderly population is at increased risk of developing and dying from COVID-19. Comorbidity is present in more than 30% of cases with COVID-19. Except for less than 1% of the total, a chronic condition has been found in all cases that died from COVID-19. Men are more than 1.5 times more likely to die from COVID-19. Evidence links aging to cytokine dysregulation and T-cell repertoire reduction, male population to relatively reduced anti-viral immunity, and COVID-19-related comorbidities to hyper inflammation. The transmission of COVID-19 is influenced by the host-related factors that are known to be associated with immune dysregulation."],"journal":"Expert Rev Clin Immunol","authors":["Saghazadeh, Amene","Rezaei, Nima"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32237901","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1080/1744666X.2020.1750954","keywords":["2019-ncov","covid-19","novel coronavirus","sars-cov2","immune-epidemiology"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Transmission"],"weight":1,"_version_":1666138490284277760,"score":196.91133},{"pmid":32459524,"title":"Obesity and COVID-19: Immune and metabolic derangement as a possible link to adverse clinical outcomes.","text":["Obesity and COVID-19: Immune and metabolic derangement as a possible link to adverse clinical outcomes.","Recent reports have shown a strong association between obesity and the severity of COVID-19 infection, even in the absence of other co-morbidities. After infecting the host cells, SARS-CoV-2 may cause a hyper-inflammatory reaction through the excessive release of cytokines, a condition known as \"cytokine storm\", while inducing lymphopenia and a disrupted immune response. Obesity is associated with chronic low-grade inflammation and immune dysregulation, but the exact mechanisms through which it exacerbates COVID-19 infection are not fully clarified. The production of increased amounts of cytokines such as TNF-alpha, IL-1, IL-6 and MCP-1 lead to oxidative stress and defective function of innate and adaptive immunity, while the activation of NLRP3 inflammasome seems to play a crucial role in the pathogenesis of the infection. Endothelial dysfunction and arterial stiffness could favor the recently discovered infection of the endothelium by SARS-CoV-2, while alterations in cardiac structure and function and the pro-thrombotic microenvironment in obesity could provide a link for the increased cardiovascular events in these patients. The successful use of anti-inflammatory agents such as IL-1 and IL-6 blockers in similar hyper-inflammatory settings like that of rheumatoid arthritis has triggered the discussion of whether such agents could be administrated in selected patients with COVID-19 disease.","Am J Physiol Endocrinol Metab","Korakas, Emmanouil","Ikonomidis, Ignatios","Kousathana, Foteini","Balampanis, Konstantinos","Kountouri, Aikaterini","Raptis, Athanasios","Palaiodimou, Lina","Kokkinos, Alexander","Lambadiari, Vaia","32459524"],"abstract":["Recent reports have shown a strong association between obesity and the severity of COVID-19 infection, even in the absence of other co-morbidities. After infecting the host cells, SARS-CoV-2 may cause a hyper-inflammatory reaction through the excessive release of cytokines, a condition known as \"cytokine storm\", while inducing lymphopenia and a disrupted immune response. Obesity is associated with chronic low-grade inflammation and immune dysregulation, but the exact mechanisms through which it exacerbates COVID-19 infection are not fully clarified. The production of increased amounts of cytokines such as TNF-alpha, IL-1, IL-6 and MCP-1 lead to oxidative stress and defective function of innate and adaptive immunity, while the activation of NLRP3 inflammasome seems to play a crucial role in the pathogenesis of the infection. Endothelial dysfunction and arterial stiffness could favor the recently discovered infection of the endothelium by SARS-CoV-2, while alterations in cardiac structure and function and the pro-thrombotic microenvironment in obesity could provide a link for the increased cardiovascular events in these patients. The successful use of anti-inflammatory agents such as IL-1 and IL-6 blockers in similar hyper-inflammatory settings like that of rheumatoid arthritis has triggered the discussion of whether such agents could be administrated in selected patients with COVID-19 disease."],"journal":"Am J Physiol Endocrinol Metab","authors":["Korakas, Emmanouil","Ikonomidis, Ignatios","Kousathana, Foteini","Balampanis, Konstantinos","Kountouri, Aikaterini","Raptis, Athanasios","Palaiodimou, Lina","Kokkinos, Alexander","Lambadiari, Vaia"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459524","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1152/ajpendo.00198.2020","keywords":["covid-19","obesity","arterial stiffness","cytokines","immune system"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967699029852161,"score":194.01189}]}